The American Association of Nurse Practitioners® (AANP) is committed to providing members with up-to-date clinical and policy resources and information related to the COVID-19 pandemic and National Emergency Declaration.
The U.S. Food and Drug Administration issued the first three emergency use authorizations (EUAs) to the Pfizer-BioNTech COVID-19 Vaccine, the Moderna COVID-19 Vaccine and the Janssen COVID-19 Vaccine. The Pfizer vaccine is for the prevention of COVID-19 caused by the SARS-CoV-2 virus in individuals 16 years of age and older. The Moderna and Janssen vaccines will be distributed in the U.S. for individuals 18 years of age and older.
The FDA notes that available data continues to support the use of two specified doses of two of the authorized vaccines at specified intervals: 21 days between the first and second dose for the Pfizer-BioNTech COVID-19 vaccine, and 28 days between the first and second dose for the Moderna COVID-19 vaccine. Meanwhile, the Janseen COVID-19 Vaccine requires just one dose.
AANP is committed to ensuring that NP have access to the latest COVID-19 vaccine information so they can educate patients on the importance of vaccination, and the association urges the public to get vaccinated at the earliest opportunity.
The CDC is tracking the latest COVID-19 vaccine news, and offers information about vaccine recommendations, how researchers are ensuring the safety of vaccines, how COVID-19 vaccines work and other details. The CDC also stresses the importance of COVID-19 vaccination for health care workers. A number of COVID-19 vaccine resources are now available, including:
In the U.S., 229,398,685 vaccine doses have been delivered, according to the CDC, with 112,046,611 people receiving at least one dose and 66,203,123 receiving two doses.
AANP is a partner organization of the COVID-19 Vaccine Education and Equity Project, which raises awareness, provides education, promotes the impact of the COVID-19 vaccine and advocates for equitable access to authorized and approved vaccines. Use the #CountMeInCOVIDVx hashtag in all of your social media posts to promote the campaign and share your reason for be "counted in" for COVID-19 vaccination.
AANP is a founding member of the COVID-19 Community Corps, of which its We Can Do This campaign aims to increase COVID-19 vaccine confidence while reinforcing basic prevention measures. Learn more about how the campaign is educating the public and find resources for your community, including fact sheets, a podcast, toolkits, tip sheets, messages for social media and more.
The NFID released a collection of frequently asked questions (FAQs) about the COVID-19 vaccines. Health care professionals and the general public can use this resource for information about mRNA vaccines, dosing timeframes, vaccine safety and vaccine administration.
HHS has produced a video series detailing the history and science of vaccines. The series is designed to provide background and clarity — via expert commentary and graphic illustration — to help viewers understand how vaccines are developed and the full strength of initiatives such as Operation Warp Speed.
The Trump Administration released the COVID-19 Vaccine Distribution Strategy, which includes two documents detailing the distribution strategy and a vaccine program interim playbook.
On Thursday, January 21, 2021, President Joe Biden released a National Strategy for the COVID-19 Response and Pandemic Preparedness. The president also issued a number of Executive Orders, including:
In addition, President Biden, first lady Jill Biden, Vice President Kamala Karris and second gentleman Doug Emhoff have all publicly received a COVID-19 vaccine to promote the safety and efficacy of the vaccine.
The CDC currently cautions that COVID-19 cases are rising and recommends the wearing of masks in public settings where other social distancing measures are difficult to maintain.
The CDC has released interim guidance for health care professionals in the U.S. to combat the spread of this illness, including but not limited to guidance on:
In the U.S., 385,064,247 tests have been reported, according to the CDC, with 32,817,246 reported as positive.
President Biden and Vice President Harris have released a seven-point plan to beat COVID-19. In addition, President Biden issued an Executive Order on January 21 to establish a COVID-19 Pandemic Testing Board and to ensure a sustainable public health workforce for COVID-19 and future health care emergencies.
NAM and the American Public Health Association have launched a nonaccredited webinar series to explore the current science about COVID-19. Webinar topics include crisis standards of care during COVID-19, the science behind social distancing and the impact of COVID-19 on long-term health.
A NAM committee has also reviewed the effectiveness of homemade fabric masks, potential effects of seasonal and temperature changes and how infected patients spread COVID-19. The committee was assembled in March at the request of the U.S. Department of Health and Human Services.
To address health disparities, particularly brought to light during the COVID-19 pandemic, the National Quality Forum has released The Care We Need, a roadmap to normalize high-quality health care for every person by 2030. The report focuses on opportunities to improve the health outcomes of people and communities, along with recommendations that emphasize the importance of a seamless system of comprehensive, accessible care designed to keep people healthy and well.
PCORI has produced a six-part, nonaccredited webinar series on COVID-19, available at no cost. Topics in the series include how incident command structures can be utilized to coordinate a response to COVID-19, nurse staffing practices and issues and the changing role of telehealth.
In partnership with the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) and in collaboration with the National Ebola and Special Pathogens Training and Education Centers (NETEC), Project ECHO has launched a series of COVID-19 Clinical Rounds. These panel discussions are designed to facilitate learning and dialog concerning COVID-19 treatment, and a number of special sessions highlight topics such as pediatrics, personal protective equipment (PPE), long-term care facilities and more.
Human-to-human transmission has been confirmed in China and other countries around the world, including within the U.S. WHO has released daily situation reports monitoring the spread, treatment recommendations and response to the outbreak. It also maintains an updated situation dashboard on COVID-19 cases globally and reports that there have been 132,730,691 confirmed cases and 2,880,726 confirmed deaths worldwide.
The CDC reports that there have been 30,737,477 total cases and 556,106 deaths in the U.S. All states are reporting community spread of COVID-19.
The United States Census Bureau has created a dashboard to show states' COVID-19 impact planning reports, nationwide demographic and economic analysis and additional data on how the pandemic is impacting communities and Americans across the U.S.
AANP is closely tracking policy developments in response to the COVID-19 pandemic.
AANP is committed to keeping you up to date, including by providing details on federal- and state-issued waivers and flexibilities for NPs and increased access to telehealth. Information included is related to Centers for Medicare and Medicaid Services (CMS) waivers, emergency state actions and licensure information and other policy guidance.
AANP conducted two surveys on the impact of COVID-19 on NPs.
AANP is compiling educational and clinical information regarding the COVID-19 pandemic, including a look at symptoms, testing, infection control, protection for health care providers and current, approved treatment options and investigational treatments. When available, information on funding and research is also shared.
Three patient education infographics, designed to provide information on common symptoms and tips on protecting oneself and others from COVID-19, are now available for download.
The first cases of the novel (new) coronavirus were reported in Wuhan, China, in December 2019. Describing a respiratory illness with symptoms of fever, cough and shortness of breath, COVID-19 is different than coronaviruses that are already known to circulate among humans, including 229E, NL63, OC43 and HKU1.
COVID-19 also differs from SARS-CoV, first reported in 2002, or MERS-CoV, first reported in 2012. However, genetic analyses have suggested that the COVID-19 may have emerged from a virus related to SARS.
Illness severity has varied, with reports ranging from very mild cases (including some with no reported symptoms) to severe cases resulting in death. Older adults, people who live in nursing homes or long-term care facilities and people with severe underlying health conditions or compromised immune systems reportedly are at higher risk of developing serious COVID-19 illness.